Seeking Alpha

NeoStem boosts patent portfolio

  • NeoStem (NBS) obtains worldwide licensing rights to three families of patents from the University of California, San Francisco, providing the company with "incremental protection" for its human Regulatory T cell ("Treg") platform.
  • The IP cover Treg's potential for treating autoimmune disorders, including Type 1 diabetes.
  • NeoStem's IP for Treg includes the rights to use 22 patents in the U.S. and other major regions. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector